The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19
GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for …

Abstract Background An ABCD-GENE (age, body mass index, chronic kidney disease,
diabetes, and CYP2C19 genetic variants) score≥ 10 predicts reduced clopidogrel …

Background In TAILOR‐PCI, genotype‐guided selection of P2Y12 inhibitors after
percutaneous coronary intervention did not significantly reduce the risk of ischemic events at …

Objectives The aim of this study was to develop a risk score integrating cytochrome P450
2C19 loss-of-function genotypes with clinical risk factors influencing clopidogrel response …

The ABCD-GENE score was constructed to identify patients with high platelet reactivity
(HPR) after 30 days of clopidogrel treatment. In our study, 1297 eligible patients with acute …

Aims Clopidogrel is prescribed for the prevention of atherothrombotic events. While
investigations have identified genetic determinants of inter-individual variability in on …

Background—Patients treated with clopidogrel who have≥ 1 loss of function alleles for
CYP2C19 have an increased risk for adverse cardiovascular events. In 2010, the US Food …

The loss-of-function hepatic cytochrome P450 (CYP) 2C19* 2 allele has been associated
with reduced clopidogrel active metabolite generation and higher ex vivo platelet reactivity …

Introduction. Clopidogrel is commonly prescribed with aspirin to reduce the risk for adverse
cardiovascular events after percutaneous coronary intervention (PCI). However, there is …

Aim: Growing evidence indicated that CYP2C19 genotypes could only explain a fraction of
the pharmacodynamic response to clopidogrel, while a number of clinical factors also have …